Publications by authors named "Arthur Petitdemange"
New-onset systemic sclerosis and scleroderma renal crisis under docetaxel.
J Scleroderma Relat Disord
October 2021
Systemic sclerosis is a rare systemic autoimmune disease characterized by microvascular impairment and fibrosis of the skin and other organs with poor outcomes. Toxic causes may be involved. We reported the case of a 59-year-old woman who developed an acute systemic sclerosis after two doses of adjuvant chemotherapy by docetaxel and cyclophosphamide for a localized hormone receptor + human epithelial receptor 2-breast cancer.
View Article and Find Full Text PDFObjectives: Due to the rarity of relapsing polychondritis (RP), no randomised clinical trial has been conducted to date and treatment remains empirical. We performed a systematic literature review to assess the efficacy of the main conventional immunosuppressants and biotherapies used in RP.
Methods: We searched MEDLINE for original articles without language restriction.
Background: Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the cornerstone of treatment of cutaneous and systemic lupus erythematosus. However, many aspects of AM prescription remain empirical. The aim of this study was to assess the modalities of AM prescription among physicians treating patients with lupus and to verify the assumption that AM use is heterogeneous and frequently at variance with international guidelines.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the shared pathogenic inflammatory pathways across various autoimmune and inflammatory diseases (AIDs), suggesting the possibility for developing targeted therapies applicable to multiple conditions.
- Researchers analyzed clinical trial registries and identified 142 targeted therapies that are being researched for at least two of the common AIDs, with rheumatoid arthritis and systemic lupus erythematosus showing significant overlap.
- The findings indicate that many therapies are effective across multiple AIDs, highlighting the need for a shift from a purely clinical classification of these diseases to one based on underlying mechanisms.
Aims: With the arrival of conventional synthetic (csDMARDs), biological (bDMARDS) and then targeted synthetic (tsDMARDs) disease-modifying anti-rheumatic drugs, the therapeutic arsenal against rheumatoid arthritis (RA) has recently expanded. However, there are still some unmet needs for patients who do not achieve remission and continue to worsen despite treatments. Of note, most randomized controlled trials show that, for methotrexate-inadequate responders, only 20% of patients are ACR70 responders.
View Article and Find Full Text PDF